Why is Astec Lifescienc falling/rising?

As of 25-Jul, Astec Lifesciences Ltd is experiencing a decline in its stock price, currently at 892.80, down by 5.7 points or 0.63%. The stock has underperformed its sector today by 0.58%, and while it is trading above its 50-day and 100-day moving averages, it is below its 5-day, 20-day, and 200-day moving averages. Over the past week, the stock has seen a slight decrease of 0.40%, and its year-to-date performance shows a significant drop of 11.16%. The company has faced challenges with a negative operating cash flow and declining net sales, which have contributed to its weak long-term fundamental strength, including a staggering -212.13% CAGR growth in operating profits over the last five years.
In the broader market context, the stock's recent performance contrasts with the benchmark, as it has consistently underperformed against the BSE500 over the last three years. While the Sensex has gained 4.25% year-to-date, Astec Lifesciences has seen a substantial decline of 11.16%. This underperformance is compounded by the company's negative results over the last four quarters and a high debt-to-EBITDA ratio, indicating a low ability to service debt. The significant drop in delivery volume and the overall negative sentiment surrounding the stock further highlight the challenges it faces in the current market environment.